Myleran (Busulfan)

Busulfan, the active ingredient in Myleran, is an alkylating agent presented as an oral tablet for oral use. It is employed in the treatment of chronic myelogenous leukemia and as part of conditioning regimens prior to bone marrow or stem cell transplantation in adult patients.

GNH USA supplies Myleran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution across regulated markets.

Busulfan is an alkylating antineoplastic agent used in specific hematologic malignancies and transplant conditioning.

Chronic myelogenous leukemia (CML): reduces leukemic cell burden and helps achieve remission. Allogeneic stem cell transplantation conditioning: creates myeloablation to enable donor cell engraftment. Autologous stem cell transplantation conditioning: facilitates collection and reinfusion of the patient’s own stem cells.

Busulfan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after dosing. - Oral mucositis: painful inflammation of the mouth lining. - Fever: low‑grade temperature elevation. - Alopecia: temporary hair loss.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Hepatic veno‑occlusive disease: blockage of small liver veins. - Seizures: neurological events, especially at high plasma concentrations. - Severe bone marrow suppression: leading to pancytopenia and heightened infection risk.

Busulfan requires careful monitoring and specific safety measures.

Dose adjustment: required in patients with hepatic impairment. Renal function: monitor as excretion may be altered. Pregnancy: category D; avoid unless benefits outweigh risks. Concomitant therapy: avoid drugs that inhibit glutathione S‑transferase. Monitoring: perform regular blood counts and liver function tests. Store at ambient temperature: keep in the original container, protect from moisture and light.

Busulfan can interact with several medicines, influencing its toxicity or efficacy.

Major Interactions (Avoid): - Azathioprine: increased myelosuppression. - Cyclophosphamide: additive bone marrow toxicity. - Chloramphenicol: impaired metabolism leading to heightened toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may alter busulfan clearance. - Antifungal azoles (e.g., fluconazole): may increase systemic exposure. - Acetaminophen: may affect hepatic metabolism and increase risk of liver injury.